Apellis Pharmaceuticals (APLS) Competitors $28.31 +1.24 (+4.58%) Closing price 04:00 PM EasternExtended Trading$28.13 -0.18 (-0.64%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, RVMD, and ABVXShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Abivax Dr. Reddy's Laboratories (NYSE:RDY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment. Which has stronger valuation and earnings, RDY or APLS? Dr. Reddy's Laboratories has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.23$663M$0.6622.34Apellis Pharmaceuticals$781.37M4.58-$197.88M-$1.82-15.55 Do analysts prefer RDY or APLS? Dr. Reddy's Laboratories presently has a consensus target price of $16.95, indicating a potential upside of 14.95%. Apellis Pharmaceuticals has a consensus target price of $33.47, indicating a potential upside of 18.23%. Given Apellis Pharmaceuticals' higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Apellis Pharmaceuticals 2 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.47 Do insiders & institutionals hold more shares of RDY or APLS? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, RDY or APLS? Dr. Reddy's Laboratories has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Does the media favor RDY or APLS? In the previous week, Apellis Pharmaceuticals had 20 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 23 mentions for Apellis Pharmaceuticals and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.28 beat Apellis Pharmaceuticals' score of 0.32 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is RDY or APLS more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Apellis Pharmaceuticals' net margin of -30.24%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Apellis Pharmaceuticals -30.24%-116.09%-26.72% SummaryDr. Reddy's Laboratories beats Apellis Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.42B$3.48B$6.18B$10.69BDividend YieldN/A2.26%5.72%4.83%P/E Ratio-15.558.2420.7722.98Price / Sales4.58481.95579.80129.94Price / CashN/A47.5937.5161.65Price / Book15.3910.6612.476.59Net Income-$197.88M-$52.56M$3.32B$276.14M7 Day Performance22.29%4.97%1.87%0.01%1 Month Performance23.03%16.48%8.40%3.60%1 Year Performance5.32%14.95%63.49%32.76% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.1007 of 5 stars$28.31+4.6%$33.47+18.2%-3.3%$3.42B$781.37M-15.55770Analyst ForecastRDYDr. Reddy's Laboratories2.8006 of 5 stars$14.36+0.1%$16.95+18.1%-7.5%$11.97B$3.81B21.7527,811VTRSViatris3.5019 of 5 stars$9.86+1.2%$10.40+5.5%-12.3%$11.36B$14.74B-3.4032,000ROIVRoivant Sciences2.7111 of 5 stars$16.21+1.1%$19.94+23.0%+48.8%$10.95B$29.05M-23.16860BBIOBridgeBio Pharma4.6007 of 5 stars$55.96+0.8%$63.94+14.3%+116.2%$10.61B$221.90M-13.68400Analyst ForecastMRNAModerna4.2934 of 5 stars$26.74-0.3%$41.81+56.4%-49.6%$10.48B$3.24B-3.555,800Trending NewsAnalyst ForecastQGENQIAGEN4.1823 of 5 stars$47.30+1.0%$49.40+4.4%+16.5%$10.41B$1.98B27.955,765Positive NewsELANElanco Animal Health2.7355 of 5 stars$20.04+1.4%$19.14-4.5%+67.7%$9.82B$4.44B23.309,000Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.5784 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.4666 of 5 stars$48.75+1.1%$74.64+53.1%+7.1%$9.02B$11.58M-10.83250Analyst ForecastABVXAbivax3.5852 of 5 stars$95.63+2.0%$114.25+19.5%+775.5%$7.30BN/A0.0061Short Interest ↓Gap Up Related Companies and Tools Related Companies RDY Alternatives VTRS Alternatives ROIV Alternatives BBIO Alternatives MRNA Alternatives QGEN Alternatives ELAN Alternatives VRNA Alternatives RVMD Alternatives ABVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts